Novozymes Biopharma triumphs in Medilink East Midlands Business Awards

| May 18, 2012 | 0 Comments

Innovation Day 2012, Thursday 17th May, The Belfry Hotel, Nottingham

Novozymes Biopharma has walked away with the Innovation Award in this year’s Medilink East Midlands business competition.  Dave Mead, Business Development Director collected the prize on behalf of the company at the Innovation Day awards evening at the Belfry Hotel, Nottingham.

Nottingham-based Novozymes Biopharma, develops and manufactures products and technologies that allow pharmaceutical manufacturers to develop innovative, safe, and more effective healthcare products. They won the Innovation Award for their tunable drug half-life extension technology which will allow significant reductions in the frequency of drug administration for patients, making the drugs more effective and less toxic. Novozymes Biopharma also walked away with the Outstanding Achievement award on the night.

Dave Mead said: “Novozymes is proud to have won the Medilink Innovation Award. The albumin-based technology is adaptable and can be used for both genetic fusion (Albufuse® Flex) or conjugation (Recombumin® Flex), providing a unique ability to tune the half-life extension of a drug. For our science to be recognised as the most innovative technology of the year, is a real testament to its potential benefit to the market.”

The Innovation Award is sponsored by Potter Clarkson LLP. Helen Johnstone, Partner, said: “The Judges were looking for something revolutionary, which they found in Novozymes’ tunable half-life extension technology. The technology allows drug manufacturers more flexibility and control of their drug design, which will lead to more effective drugs at smaller doses, improved quality of life for patients and reduced healthcare costs.”

In addition to Novozymes Biopharma, four companies won Medilink awards in this year’s competition; they are Advancis Medical for Export Achievement; ViVOSmart Medical Devices Ltd for Partnership with the NHS, and XenoGesis Limited for Best Start Up, further evidence of the East Midlands’ impact and influence in the healthcare and bioscience business sector. The creativity and innovation shown by these companies has increased jobs, profits and business growth which should contribute to the region’s continued climb out of recession. They are also playing a major part in improving patient care, especially in the community, resulting in the cost-effective delivery of healthcare services.

The Awards ceremony was supported through the Healthcare and Bioscience iNet programme, which is part-financed by the European Regional Development Fund (ERDF), and took place on the evening following Medilink’s Innovation Day, a conference for the region’s leading businesses and academics in the sector.

Speaking after the awards were announced, Dr Darren Clark, Chief Executive of Medilink East Midlands commented: “The innovation that won Novozymes Biopharma this award could be the solution to the problem of poor patient adherence to prescribed medication. It’s a problem that costs the US health system an estimated $290 billion in avoidable spending every year, so we’re delighted to recognise Novozymes Biopharma’s hugely important innovation in this area.”

Novozymes Biopharma is automatically entered into the Medilink UK national awards which will take place in early 2013.

ENDS

Photo

Dr. Darren Clark, Dave Mead and Helen Johnstone

Dave Mead, Business Development Director is available for interview after the Awards on: 0115 9553355. www.biopharma.novozymes.com

Medilink contact:

Louise Third, Integra Communications: 0115 912 4350 / 07773 288342 louise@integracommunications.co.uk

Please call Louise for photography and caption confirmation.

NOTES

The Awards

The five awards’ categories and (sponsors) were: Best Start Up (Smith Cooper Accountants); Export Achievement (Shakespeares); Partnership with the NHS (NHS Midlands and East); Innovation (Potter Clarkson LLP) and Outstanding Achievement (Morningside Pharmaceuticals).

Medilink East Midlands

Medilink East Midlands is the life science industry association for the East Midlands whose aim is to help healthcare and bioscience companies establish, develop and grow. Medilink’s highly knowledgeable team is a proven and trusted source of expert assistance and provides a range of specialist support services to its network of over 4000 contacts

The Healthcare and Bioscience iNet is an initiative, delivered by Medilink East Midlands, that brings together businesses, universities, and the NHS to develop new technologies, processes, products and services in order to build a healthy economy.

The Healthcare and Bioscience iNet project is part financed by the European Regional Development Fund Programme 2007 to 2013. The Department for Communities and Local Government is the managing authority for the European Regional Development Fund Programme, which is one of the funds established by the European Commission to help local areas stimulate their economic development by investing in projects which will support local businesses and create jobs. For more information visit www.communities.gov.uk/erdf

About Potter Clarkson

Potter Clarkson LLP is a leading firm of European patent and trade mark attorneys.  We have over 50 patent and trade mark professionals working together at a single site.  Their technical qualifications and experience are outstanding and many are recognised as leaders in their field.

The patent professionals are divided into five specialist groups:  Biotechnology & Pharmaceuticals; Chemistry; Designs & Engineering; and Electronics & Computing; Clean Technologies. There is much interaction between these groups and our single-site arrangement makes it easy to put together a multi-disciplinary team.

A dedicated Trade Mark group deals with trademarks and every aspect of branding.

For further information, please refer to www.potterclarkson.com

Contact: Kerry Meadwell, Business Support Co-ordinator. Tel: 0115 9552211 Email: kerry.meadwell@potterclarkson.com

 

 

 

Comments are closed.